Mitsui Chemicals outlines rationale and targets for JSR acquisition
- Mitsui Chemicals expects FY2030 operating income before special items to exceed ¥300 billion across its specialty and polymer science businesses.
- The FY2030 ICT operating income target is more than ¥190 billion, including JSR, existing businesses and synergies.
- Interest expenses are expected to reach about ¥60 billion in FY2029 or FY2030; permanent financing is targeted within approximately one year of closing.
- Equity financing of up to ¥150 billion is under consideration, alongside divestitures and other funding options.
Strategic rationale
Mitsui Chemicals says acquiring JSR will accelerate its portfolio transformation and strengthen ICT, particularly semiconductor materials. It cited complementary product portfolios and JSR’s position as the No. 2 company in the global photoresist market. The companies plan to combine high-growth ICT with stable-growth Life & Healthcare in a global specialty business, while B&GM and Mobility will form a polymer science business.
Synergies and integration
Expected benefits include joint development and customer access, with products such as JSR resists and Mitsui Chemicals’ EUV pellicles developed and proposed as part of an integrated lithography process. The companies will also assess efficiencies across sites, outsourced functions, supply chains, logistics and overlapping R&D. Mitsui Chemicals cited the proximity of JSR’s Yokkaichi R&D site and its Nagoya site as an opportunity for researcher collaboration and shared facility use.
Financial outlook
For FY2030, Mitsui Chemicals targets more than ¥300 billion in combined operating income before special items, including more than ¥190 billion from ICT. It expects net income attributable to owners of the parent of about ¥150 billion. Interest expenses are expected to reach approximately ¥60 billion in FY2029 or FY2030. Bridge financing is planned at closing, with a transition to permanent financing targeted within about one year. Equity financing of up to ¥150 billion is under consideration.
Approvals
The company does not expect the combination to significantly increase market share in any product, but acknowledges that antitrust reviews may take longer than anticipated and says it will respond to information requests from relevant authorities.
Source: Mitsui Chemicals